The second of these two tests to be PMA approved by the FDA in 2016 was the cobas® EGFR Mutation Test by Roche Diagnostics, which analyses the mutations in the EGFR gene in patient plasma samples, and is a companion diagnostic for non-small-cell lung cancer [144]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.